SGLT-2i/DPP-4i COMBINATION TREATMENT FOR T2DM PATIENTS AT HIGH CV RISK

Dr Saiful Bahari Kassim, a consultant endocrinologist, diabetes specialist and obesity physician, outlines the findings of cardiovascular outcome trials involving patients with type 2 diabetes mellitus. Saiful also shares a case presentation whereby a T2DM patient at high cardiovascular risk is treated with a fixed dose combination of a sodium/glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 enzyme inhibitor.